Free Trial

Inhibikase Therapeutics (IKT) Competitors

Inhibikase Therapeutics logo
$1.77 -0.08 (-4.32%)
Closing price 04:00 PM Eastern
Extended Trading
$1.80 +0.03 (+1.69%)
As of 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IKT vs. PGEN, ARVN, TBPH, SAGE, ORGO, TSHA, ABVX, BCYC, BCAX, and ORKA

Should you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include Precigen (PGEN), Arvinas (ARVN), Theravance Biopharma (TBPH), Sage Therapeutics (SAGE), Organogenesis (ORGO), Taysha Gene Therapies (TSHA), Abivax (ABVX), Bicycle Therapeutics (BCYC), Bicara Therapeutics (BCAX), and Oruka Therapeutics (ORKA). These companies are all part of the "pharmaceutical products" industry.

Inhibikase Therapeutics vs. Its Competitors

Precigen (NASDAQ:PGEN) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

33.5% of Precigen shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 47.1% of Precigen shares are held by insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Inhibikase Therapeutics has lower revenue, but higher earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precigen$3.92M118.22-$126.24M-$0.56-2.80
Inhibikase TherapeuticsN/AN/A-$19.03M-$2.67-0.66

Precigen has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Inhibikase Therapeutics has a net margin of 0.00% compared to Precigen's net margin of -3,728.87%. Precigen's return on equity of -279.20% beat Inhibikase Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Precigen-3,728.87% -279.20% -79.74%
Inhibikase Therapeutics N/A -350.63%-201.82%

In the previous week, Precigen had 2 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 3 mentions for Precigen and 1 mentions for Inhibikase Therapeutics. Precigen's average media sentiment score of 1.02 beat Inhibikase Therapeutics' score of 0.67 indicating that Precigen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Precigen
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Inhibikase Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Precigen currently has a consensus target price of $6.00, suggesting a potential upside of 282.17%. Inhibikase Therapeutics has a consensus target price of $6.50, suggesting a potential upside of 267.23%. Given Precigen's stronger consensus rating and higher probable upside, equities analysts plainly believe Precigen is more favorable than Inhibikase Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Precigen
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Inhibikase Therapeutics
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Precigen beats Inhibikase Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Inhibikase Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IKT vs. The Competition

MetricInhibikase TherapeuticsBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$131.59M$273.51M$5.70B$21.12B
Dividend YieldN/AN/A4.69%3.60%
P/E Ratio-0.66N/A28.0728.44
Price / SalesN/A364.38448.5760.38
Price / CashN/A22.4436.2222.92
Price / Book0.9912.418.664.69
Net Income-$19.03M-$106.40M$3.25B$995.51M
7 Day Performance-3.80%4.86%4.20%1.64%
1 Month Performance5.99%25.43%10.82%5.92%
1 Year Performance10.63%11.08%34.70%11.50%

Inhibikase Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IKT
Inhibikase Therapeutics
1.484 of 5 stars
$1.77
-4.3%
$6.50
+267.2%
+12.8%$131.59MN/A-0.666News Coverage
PGEN
Precigen
3.8466 of 5 stars
$1.95
+6.6%
$6.00
+207.7%
-2.1%$575.60M$4.20M-3.48190Positive News
ARVN
Arvinas
4.0032 of 5 stars
$7.87
+1.0%
$20.29
+157.8%
-72.7%$574.43M$263.40M-11.92420News Coverage
Upcoming Earnings
TBPH
Theravance Biopharma
1.7803 of 5 stars
$11.47
+1.5%
$16.60
+44.7%
+11.3%$573.50M$64.38M-9.72110
SAGE
Sage Therapeutics
3.4224 of 5 stars
$9.15
-1.3%
$8.75
-4.4%
-15.6%$572.97M$41.24M-1.58690Upcoming Earnings
ORGO
Organogenesis
4.5372 of 5 stars
$4.49
+4.4%
$6.00
+33.6%
+53.2%$569.56M$482.04M-26.41950
TSHA
Taysha Gene Therapies
4.2565 of 5 stars
$2.64
flat
$8.17
+209.3%
+15.6%$566.70M$8.33M-7.76180
ABVX
Abivax
2.4067 of 5 stars
$8.83
+6.8%
$31.00
+251.1%
+488.7%$560.44MN/A0.0061Trending News
Analyst Forecast
Analyst Revision
Gap Down
High Trading Volume
BCYC
Bicycle Therapeutics
3.8213 of 5 stars
$8.08
+1.0%
$25.00
+209.4%
-63.5%$559.54M$35.28M-2.57240
BCAX
Bicara Therapeutics
2.0924 of 5 stars
$10.18
+4.8%
$31.86
+213.0%
N/A$555.22MN/A0.0032
ORKA
Oruka Therapeutics
2.6959 of 5 stars
$14.70
+3.3%
$40.38
+174.7%
N/A$550.37MN/A-3.26N/AUpcoming Earnings
Analyst Forecast

Related Companies and Tools


This page (NYSE:IKT) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners